StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$31.74+1.76 (+5.87%)

Close on Nov 18, 2026Market cap $373.06MP/E –Yield –

Surrozen operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Surrozen's operating income for the twelve months ending Jun 30, 2026 was -$44.35M. For fiscal 2025 it was -$42.09M. The highest annual figure on record is -$25.54M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.09M–
FY2024Dec 31, 2024-$25.54M–
FY2023Dec 31, 2023-$45.78M–
FY2022Dec 31, 2022-$44.34M–
FY2021Dec 31, 2021-$54.39M–
FY2020Dec 31, 2020-$32.81M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.37M–
Q1 FY2026Mar 31, 2026-$10.46M–
Q4 FY2025Dec 31, 2025-$12.64M–
Q3 FY2025Sep 30, 2025-$10.89M-983.5%
Q2 FY2025Jun 30, 2025-$9.02M–
Q1 FY2025Mar 31, 2025-$9.55M–
Q4 FY2024Dec 31, 2024-$8.59M–
Q3 FY2024Sep 30, 2024$1.23M–
Q4 FY2023Dec 31, 2023-$9.72M–
Q3 FY2023Sep 30, 2023-$11.19M–
Q2 FY2023Jun 30, 2023-$10.28M–
Q1 FY2023Mar 31, 2023-$14.59M–
Q4 FY2022Dec 31, 2022-$2.17M–
Q3 FY2022Sep 30, 2022-$13.61M–
Q2 FY2022Jun 30, 2022-$14.07M–
Q1 FY2022Mar 31, 2022-$14.49M–
Q4 FY2021Dec 31, 2021-$15.00M–
Q3 FY2021Sep 30, 2021-$13.71M–
Q2 FY2021Jun 30, 2021-$12.66M–
Q1 FY2021Mar 31, 2021-$13.03M–
Q4 FY2020Dec 31, 2020-$10.84M–
Q3 FY2020Sep 30, 2020-$8.64M–

More Surrozen figures

See a number that looks wrong?